SEC Comment Letter 0000000000-24-013738 to Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635) (RNAZ)
Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635)
Date: Dec. 13, 2024 · CIK: 0001829635 · Accession: 0000000000-24-013738
AI Filing Summary & Sentiment
File numbers found in text: 333-283668
Letter
December 13, 2024 Thomas Fitzgerald Interim Chief Executive Officer Transcode Therapeutics, Inc. 6 Liberty Square, #2382 Boston, MA 02109 Re:Transcode Therapeutics, Inc. Registration Statement on Form S-1 Filed December 6, 2024 File No. 333-283668 Dear Thomas Fitzgerald: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Adam Johnson
Show Raw Text
December 13, 2024
Thomas Fitzgerald
Interim Chief Executive Officer
Transcode Therapeutics, Inc.
6 Liberty Square, #2382
Boston, MA 02109
Re:Transcode Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 6, 2024
File No. 333-283668
Dear Thomas Fitzgerald:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Adam Johnson